How Botulinum Neurotoxin Light Chain A1 Maintains Stable Association with the Intracellular Neuronal Plasma Membrane

Alexander P. Gardner 1, Joseph T. Barbieri 1,* and Sabine Pellett 2,*

1 Microbiology and Immunology, Medical College, Wisconsin 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
2 Department of Bacteriology, Microbial Sciences Building, University of Wisconsin-Madison, 1550 Linden Dr., Madison, WI 53706, USA
* Correspondence: jtb01@mcw.edu (J.T.B.); sabine.pellett@wisc.edu (S.P.)

Abstract: Botulinum neurotoxin serotype A (BoNT/A) is the most potent protein toxin for humans and is utilized as a therapy for numerous neurologic diseases. BoNT/A comprises a catalytic Light Chain (LC/A) and a Heavy Chain (HC/A) and includes eight subtypes (BoNT/A1–A8). Previously we showed BoNT/A potency positively correlated with stable localization on the intracellular plasma membrane and identified a low homology domain (amino acids 268–357) responsible for LC/A1 stable co-localization with SNAP-25 on the plasma membrane, while LC/A3 was present in the cytosol of Neuro2A cells. In the present study, steady-state- and live-imaging of a cytosolic LC/A3 derivative (LC/A3V) engineered to contain individual structural elements of the A1 LDH showed that a 59 amino acid region (275–334) termed the MLD was sufficient to direct LC/A3V from the cytosol to the plasma membrane co-localized with SNAP-25. Informatics and experimental validation of the MLD-predicted R1 region (an α-helix, residues 275–300) and R2 region (a loop, α-helix, loop, residues 302–334) both contribute independent steps to the stable co-localization of LC/A1 with SNAP-25 on the plasma membrane of Neuro-2A cells. Understanding how these structural elements contribute to the overall association of LC/A1 on the plasma membrane may identify the molecular basis for the LC contribution of BoNT/A1 to high potency.

Keywords: botulinum toxin; bacterial toxins; SNAP-25; intracellular trafficking; protein modeling

Key Contribution: Transition of a cytosolic LC/A3 derivative (LC/A3V) engineered to contain individual structural elements of the A1 Low Homology Domain showed that A1 amino acids 275–334 were sufficient to direct LC/A3V from the cytosol to stable localization on the plasma membrane. Protein modeling and experimental support predicted R1 (an α-helix, residues 275–300) and R2 (a loop, α-helix, loop, residues 302–334) contributed independent steps for stable co-localization of LC/A1 with SNAP-25 on the plasma membrane of Neuro-2A cells.

1. Introduction

Botulinum neurotoxin (BoNT), the most potent toxin known to humans with an estimated lethal dose (LD50) of 1 ng/kilogram of body weight, are a family of protein toxins produced by several Clostridia species [1,2]. Seven immunologically distinct BoNT serotypes exist, A–G [3,4], and some Clostridia carry two or even three bont serotypes or possess a silent bont [5]. Bont gene clusters also vary among serotypes and subtypes of Clostridia, indicating that the entire gene clusters have undergone horizontal gene transfer and recombination, leading to diverse protein toxins [6]. In addition, several non-clostridial bacteria produce BoNT-like proteins, which share overall sequence similarity with the BoNTs [7–11].

BoNTs are produced as 150-kDa single-chain proteins that are post-translationally cleaved into disulfide-linked di-chains by a host or endogenous proteases that are classic AB-type bacterial toxins [12–15]. Cleavage is essential for maximal BoNT potency. For
example, di-chain BoNT/E has been reported to be ~100-fold more toxic than single-chain BoNT/E [16]. The BoNT chains consist of an N-terminal ~50 kDa catalytic A subunit, Light Chain (LC) [17], and a C-terminal ~100 kDa host-receptor binding/translocation B subunit, Heavy Chain (HC) [18]. BoNT LCs are zinc-metalloproteases containing an (H-E-X-X-H) motif for zinc coordination and cleave neuronal Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptors (SNARE) at unique sites [3]. BoNT HC possesses two domains, the translocation domain (HN) and the receptor binding domain (HC) [19]. The ~80-N-terminal amino acids of the HN, termed the belt, wrap around the LC within the catalytic groove and are hypothesized to maintain LC inactive until dissociated from HC [20,21].

BoNT/A entry into neurons follows a multi-step process. First, BoNT-HC binds a polysialoganglioside, such as GT1b, on the surface of resting neurons [22], followed by binding to the BoNT/A protein receptor, Synaptic Vesicle Protein-2 (SV2), which is exposed on the surface of the depolarized plasma membrane after synaptic vesicle (SV) fusion to the plasma membrane [23]. Upon SV recycling, surface-bound BoNT is sequestered within the SV lumen [24]. As the SV matures, the lumen of the SV acidifies as the Na\(^+\)–K\(^+\)ATPase pump reloads neurotransmitters with a proton into the lumen [25]. Acidification of the SV lumen to pH of 4–5 triggers HN to embed into the membrane of the SV, forming a pore ~15 Å in diameter [26], which allows the unfolded LC to translocate through the HN into the cytosol [27]. How LC translocates through the membrane is elusive but may follow the tunnel- or cleft-model for protein translocation [28], and translocation may be initiated at the LC C terminus [29]. After translocation, the LC-HN interchain disulfide is reduced via the thioredoxin reductase–thioredoxin system, followed by LC refolding aided by HSP-90 and HN [30,31]. BoNT/A LC (LC/A) then cleaves the substrate SyNaptosomal Associated Protein of 25 kDa (SNAP-25) [32] on the intracellular face of the plasma membrane. While previous studies have demonstrated LC/A1 localizes to the plasma membrane [33–35], the molecular mechanisms of intracellular LC trafficking to the membrane-bound SNAP-25 have not yet been elucidated. Deciphering molecular interactions involved in intracellular BoNT LC trafficking is fundamental to our understanding of the neuronal cell intoxication pathways and pathology caused by these toxins.

Several BoNT serotypes include genetic variants, which are currently defined as a new subtype denoted by numbers after the serotype letter if they differ by >2.3% at the primary amino acid level [36]. These BoNT subtypes retain sensitivity to serotype-specific antisera, and some subtypes possess unique biological activity. For example, BoNT/A comprises eight subtypes, A1–A8 [37,38], where BoNT/A1 possesses high potency and a long duration of action, while BoNT/A4 shows low potency, and BoNT/A3 has a short duration of action [39].

In a previous study, we observed predominant cytosolic localization of LC/A3 and determined the N terminus of LC/A and a region of low homology (LHD) between LC/A1 and LC/A3 traffic LC/A1 to the plasma membrane [40]. These studies also characterized an LC/A3 variant (LC/A3V) as a cytosolic protein. LC/A3V proved to be a platform to resolve the role of the N terminus as a facilitator of LC/A1-intracellular vesicle interactions and the LHD as a facilitator of LC/A-plasma membrane interactions. Overall, the N-terminal- and LHD-mediated interactions were independent, sequential, and additive for the movement of LC/A1 from the cytosol to the plasma membrane [35].

Since BoNT/A potency correlates with LC trafficking along vesicles and association with the plasma membrane [35,41], we have further characterized LC/A1 localization with the plasma membrane in this study. Initial experiments localized the membrane targeting capacity to the Low Homology Domain of LC/A1 (amino acids 268–357), which was divided into three structural regions (R1–R3) based upon a co-crystal of LC/A1 bound to SNAP-25 (PDB: 1XTG) [42]. Steady-state- and live time-lapse-imaging showed that while individual A1 R regions did not direct LC/A3V to the plasma membrane, the combined A1 R1:R2 regions, termed the Membrane Localization Domain (MLD) efficiently targeted LC/A3V to the plasma membrane, which involved interactions with SNAP-25. The current
study used informatics and experimental validation to resolve how regions R1 and R2 are required to co-localize BoNT/A1 stably with SNAP-25 on the plasma membrane of Neuro2A (N2A) cells, enabling the development of a molecular model for LC/A localization.

2. Results

2.1. Structural Analysis of the Low Homology Domain of LC/A1 Reveals Three Distinct Structural Regions

The current study sought to establish how the previously identified LHD (268–357) mediated LC/A1 association with the plasma membrane [35]. A co-crystal of LC/A1 bound to SNAP-25 (residues 146–204 (PDB: 1XTG)) and the recently solved crystal structure of LC/A3 [43] showed the LHD to be organized into three sequential structural regions (R1–R3 (Figure 1). R1, residues 275–300, included an α-helix; R2, residues 302–334, included a loop, α-helix, and loop; and R3, residues 335–357, included an α-helix, loop, and α-helix. Assessment of the LC/A1-SNAP-25 co-crystal showed R1 was distanced from bound SNAP-25, R2 had ionic and hydrogen bonds with bound SNAP-25, and R3 had a single ionic bond bound to SNAP-25 [42]. Next, we determined if R1, R2, and R3 contributed to the stable association of LC/A1 on the inner plasma membrane of N2A cells [35,40].

Figure 1. Co-crystal structure of the Botulinum neurotoxin LC/A1 and SNAP-25 (PDB: 1XTG). (A) The structure of LC/A1 is gray with regions of the LHD colored, with R1 in blue, R2 in smudge green, R3 in wheat, and SNAP-25 in magenta. (B) Enhancement of the R1:R2:R3 with SNAP-25, with R1 in blue, R2 in smudge green, R3 in wheat, and SNAP-25 in magenta. (C) Distances between potential non-covalent interactions were measured with PyMOL. R2 of LC/A1 is highlighted in smudge green, R3 of LC/A1 is highlighted in wheat, and SNAP-25 is highlighted in magenta.

2.2. Regions R1 and R2 of the A1 LHD Target LC/A3V to the Plasma Membrane

LC/A3V is a cytosolic protein when ectopically expressed in N2A cells, and replacing the A3 LHD with A1 LHD transitioned LC/A3V from the cytosol to the plasma membrane [35]. Here, LC/A3V was constructed, in which individual (R1, R2, or R3) or dual (R1:R2, R2:R3, or R1:R3) regions of the LHD with the corresponding A1 region and fusion proteins with Enhanced Green Fluorescent Protein (EGFP)-LC/A3V(A1 R) were expressed in N2A cells (Table 1). Cells were imaged to measure the transition from the cytosol to the plasma membrane (Supplemental Figure S1). Western blotting showed that each LC/A3V(A1 R) chimera was expressed in N2A cells with the appropriate molecular weight and at similar expression levels (Supplemental Figure S2).
Table 1. GFP-LC/A3V (A1 R) chimeras.

| LC/A3V(A1-LHD) Chimeras * | Designation | Chimera Schematic |
|---------------------------|-------------|-----------------|
| EGFP-LC/A3V(A1 275–300)   | LC/A3V(R1)  | ![Chimera Schematic](GFP LC/A3V R1) |
| EGFP-LC/A3V(A1 302–334)   | LC/A3V(R2)  | ![Chimera Schematic](GFP LC/A3V R2) |
| EGFP-LC/A3V(A1 335–357)   | LC/A3V(R3)  | ![Chimera Schematic](GFP LC/A3V R3) |
| EGFP-LC/A3V(A1 275–334)   | LC/A3V(R1:R2) [MLD] | ![Chimera Schematic](GFP LC/A3V R1 R2) |
| EGFP-LC/A3V(A1 302–357)   | LC/A3V(R2:R3) | ![Chimera Schematic](GFP LC/A3V R2 R3) |
| EGFP-LC/A3V(A1 275–300, 335–357) | LC/A3V(R1:R3) | ![Chimera Schematic](GFP LC/A3V R1 R3) |
| EGFP-LC/A3V (A1 268–357)  | LC/A3V(LHD) | ![Chimera Schematic](GFP LC/A3V LHD) |
| EGFP-LC/A3V (A1 1–17, 275–334) | LC/A3V(A1 N, A1 R1:R2) [MLD] | ![Chimera Schematic](GFP LC/A3V A1 R1 R2) |
| EGFP-LC/A3V (A1 287–334)  | LC/A3V(A1-287-334) | ![Chimera Schematic](GFP LC/A3V A1-287-334) |
| EGFP-LC/A3V (A1 275–334) T306A, T307A, Y312A | LC/A3V(A1MLD-AAA) | ![Chimera Schematic](GFP LC/A3V AAA) |

* Chimeras utilized LC/A3V (residues 1–446) as a platform, exchanging regions from LC/A1 LHD. 1 MLD: membrane localization domain residues 275–334 from LC/A1. 2 LHD: low homology domain residues 268–357 from LC/A1.

At steady-state, individual A1 R regions did not transition cytosolic LC/A3V from the cytosol to the plasma membrane (Figure 2). In contrast, the dual-A1 R region chimera targeted LC/A3V(R1:R2) to the plasma membrane, while LC/A3V(R2:R3) and LC/A3V(R1:R3) were expressed in the cytosol. Thus, A1 R1:R2 was necessary and sufficient to target LC/A3V to the plasma membrane.

![Intracellular localization of GFP-LC/A3V (A1-LHD) chimeras.](Fig2)

Figure 2. Intracellular localization of GFP-LC/A3V (A1-LHD) chimeras. (Left) After overnight transfections with EGFP-LC/A derivatives and fixation with 4% paraformaldehyde, N2A cells were imaged for EGFP fluorescence (excitation 488 nm, emission 509 nm). Representative images show the steady-state intracellular localization of CONTROL (EGFP, EGFP-LC/A1, EGFP-LC/A3V), SINGLE (EGFP-LC/A3V (A1 R1), EGFP-LC/A3V (A1 R2), EGFP-LC/A3V (A1 R3)), or DOUBLE (EGFP-LC/A3V (A1 R1:R2), EGFP-LC/A3V (A1 R2:R3), EGFP-LC/A3V (A1 R1:R3)), and EGFP-LC/A3V (A1- LHD). (Right) Percentage of cells containing membrane signal for 7 h post-transfection and overnight. Ten random fields were selected and counted for membrane localization with wheat germ agglutinin. Mean and SEM were evaluated as described previously [35]; ns—not significant.

At 7 h post-transfection, when EGFP fluorescence was initially detected, LC/A3V(A1 R) chimeras showed similar localization as observed for steady-state expression; only LC/A3V(R1:R2) localized on the plasma membrane (Figure 2). Live imaging at 7 h post-
transfection also showed a stable accumulation of LC/A3V(R1:R2) on the plasma membrane directly from the cytosol with no observed membrane dissociation over a 10 min measurement (Figure 3). Thus, the exchange of only A1 R1:R2 into LC/A3V was necessary and sufficient to target LC/AV3 from the cytosol to the plasma membrane, similar to LC/A3V(A1 LHD) described earlier [35]. We also noted that the association of LC/A3V(R1:R2) was stable on the plasma membrane. We termed this newly defined region, which spans amino acids 275–334, the membrane localization domain (MLD).

2.3. The A1 MLD and N Terminus Have Additive Functions in the Transition of LC to Vesicles, and the Plasma Membrane

Earlier studies showed that the N terminus and the LHD of LC/A1 contribute in an additive manner to target LC/A3V from the cytosol to vesicles and then to the plasma membrane, respectively [35]. Therefore, the A1 MLD was tested as a minimal substitute for the A1 LHD to coordinate the transition of LC/A1 from vesicles to the plasma membrane. Utilizing the cytosolic

![Figure 3. Time-lapse imaging of GFP-LC/A3V (A1-LHD) chimeras.](image-url)
LC/A3V platform, EGFP-LC/A3 fusion proteins were created, replacing the MLD and 17 aa N-terminal regions with the corresponding regions of A1, and expressed in N2A cells. At 7 h post-transfection, time-lapse imaging showed LC/A3V(A1 N, A1 MLD) associated with intracellular vesicles with stable accumulation on the plasma membrane (Figure 4) [35]. Similar to the A1 LHD, A1 MLD coordinated with the N terminus to anterograde traffic LC/A3V from the cytosol to the plasma membrane.

![Figure 4](image.png)

**Figure 4.** A1 MLD retains the LHD function. (A) Representative images show the steady-state intracellular localization of EGFP-A3V(A1 N, A1 MLD) residues 1–17 and 275–334 and EGFP-A3V(A1 N, A1 LHD) residues 1–17 and 268–357, indicated with a cartoon schematic. (B) After a seven-hour transfection, EGFP-A3V(A1 N, MLD). Live cell images were obtained every 10 s for 600 s; the initial frame (0 s) and final frame (600 s) are shown. (C) Percentage of cells containing membrane fluorescence for 7 h post-transfection and overnight were analyzed. Mean and SEM were evaluated as described previously [35]; ns—not significant.

2.4. Role of A1 R1:R2 in MLD Transition of LC/A3V from the Cytosol to the Plasma Membrane

Properties of R1. Sequence alignment showed that the N-terminal residues 275–286 of A1-R1 are polar and acidic, while A3-R1 residues are polar and basic (Figure 5A) [43]. Thus, a chimera containing the N terminus of A3-R1 fused to the C terminus of A1-R1 (A1-287–334) was engineered to investigate the contribution of the N-terminal region of A1-R1 in targeting LC/A3V from the cytosol to the plasma membrane. At 7 h- and steady-state-post-transfection, LC/A3V(A1-287–334) was cytosolic, analogous to LC/A3V (Figure 5B,C). Time-lapse imaging 7 h post-transfection showed LC/A3V(A1-287–334) retained a cytosolic phenotype with no detected temporal accumulation at the plasma membrane (Figure 5D). Together, the steady-state and time-lapse imaging indicate that A1-R1 (residues 275–286) is necessary to localize LC/A3V to the plasma membrane.
Properties of R2. Using the LC/A1-SNAP-25 co-crystal structure (PDB: 1XTG) (Figure 6A), R2 residue Y312 was reported to bond with SNAP-25 D172, N174, and R176 [42, 43]. Further examination of the LC/A1-SNAP-25 co-crystal structure also predicted two additional R2 residues, T306 and T307, to bind SNAP-25 R176 and Q177, respectively (Figure 6A). Site-directed mutagenesis of T306, T307, and Y312 to A resulted in a new chimera (MLD-A306A307A312, termed MLD-AAA). At both 7h- and steady-state-post-transfection, LC/A3V(A1MLD-AAA) was expressed as a cytosolic protein in all transfected cells. A subpopulation of transfected cells ~8%, LC/A3V(A1MLD-AAA) that were cytosolically expressed also possessed detectable localization on the plasma membrane, indicating that LC/A3V(A1MLD-AAA) that were cytosolically expressed also possessed detectable localization on the plasma membrane, indicating that LC/A3V(A1MLD-AAA) was less stable on the plasma membrane than LC/A3V(A1MLD) with the diffusion of LC/A3V(A1MLD-AAA) into the cytosol during the 10 min exposure (Figure 6D, time lapse images) and stable plasma membrane bound LC/A3V(A1MLD-AAA) (Figure 6D 0 sec, upper right corner of plasma membrane bound LC/A3V(A1MLD-AAA) (Figure 6D 0 sec, upper right corner of plasma membrane bound LC/A3V(A1MLD-AAA) (Figure 6D 0 sec, upper right corner of plasma membrane bound LC/A3V(A1MLD-AAA) (Figure 6D 0 sec, upper right corner of plasma membrane bound LC/A3V(A1MLD-AAA) (Figure 6D 0 sec, upper right corner of plasma membrane bound LC/A3V(A1MLD-AAA) (Figure 6D 0 sec, upper right corner of...
These findings showed that alanine mutations at T306, T307, and Y312 transitioned LC/A3V(A1MLD-AAA) to the cytosol, with ~8% also bound either stably or reversibly on the plasma membrane relative to the stable membrane association of LC/A3V(A1MLD), implicating a role for A1R2 in the interaction with SNAP-25 on the plasma membrane.

Figure 6. MLD-SNAP-25 interaction within the R2 is necessary for stable plasma membrane association of LC/A1. (A) The LC/A1-SNAP-25 co-crystal crystal structure (PDB: 1XTG) was analyzed for possible interactions. The distances between potential non-covalent interactions were measured with PyMOL. R2 of LC/A1 is highlighted in smudge green, with SNAP-25 highlighted in magenta. (B) The representative image shows the steady-state intracellular localization of EGFP-A3V(A1 MLD) AAA. (C) Percentage of cells containing membrane fluorescence for 7 h post-transfection and overnight were analyzed. Mean and SEM were evaluated as described previously [35]; **** p < 0.0001. (D) After a seven-hour transfection, EGFP-A3V(A1MLD-AAA) was imaged as indicated above. Red circles indicate membrane localized EGFP-LC/A3V(A1MLD-AAA) that diffused into the cytosol over 240 s. Live cell images were obtained every 10 s for 600 s; the indicated time frames are shown.

2.5. The LC MLD and Membrane Localization Are Conserved amongst BoNT/A Subtypes Other Than A3

Clustal alignment of BoNT/A(A1–A8) showed the MLDs of BoNT/A1, /A5, /A6, and /A8 MLD were identical (Figure 7). The two amino acid differences, V293 and I304, of BoNT/A2 compared to A1 do not influence intracellular localization since LC/A2 localizes on the plasma membrane [35]. The MLD of BoNT/A4 had six amino acid changes relative to BoNT/A1 at R1 (K279, K280, S283) and R2 (A327, T328, and I332). Despite these six amino acid
changes, EGFP-LC/A4 was expressed in N2As primarily as a plasma membrane-localized protein (Figure 8), indicating these residues do not contribute to membrane localization. The MLD of BoNT/A7 had four residue changes relative to BoNT/A1 in R1: E292, V293, I296, and in R2 I304. Despite these four amino acid changes, EGFP-LC/A7 was expressed in N2As primarily as a plasma membrane-localized protein (Figure 8), indicating these residues do not contribute to membrane localization. Extrapolation of the data on LC/A1, /A2, /A4, and /A7 predicts LC/A5, /A6, and /A8 will localize at the plasma membrane, as the MLDs are identical to LC/A1. Thus, among the BoNT/A subtypes, only BoNT/A3 shows limited membrane localization [35].

**Figure 7.** Clustal Omega alignment of BoNT/A subtypes residues 275–334. Alignment of LC/A1 ACW83608, LC/A7 AFV13854, and LC/A8 AJA05787 were aligned using Clustal Omega [44]. Number and secondary structure elements (green α-helix) are shown for the LC/A subtypes. Percent identity (PID) was determined off the LC/A1 sequence. The image was adapted by the MView tool [45]. Background indicates conserved residue, and the color schematic corresponds to the side chain properties; the key is below the sequence.

![Alignment of BoNT/A subtypes residues 275–334](image)

**Figure 8.** Intracellular localization of LC/A4 and LC/A7. N2A cells were transfected with pEGFP-LC/A4 or LC/A7. After overnight transfections, N2A cells were fixed with 4% paraformaldehyde and imaged for EGFP fluorescence (excitation 488 nm, emission 509 nm). (A) A Representative image shows the steady-state intracellular localization of EGFP-LC/A4 and EGFP-LC/A7, with white arrows indicating membrane localization. (B) Percentage of cells containing membrane fluorescence. Ten random fields were selected and counted for membrane localization. Mean and SEM were evaluated as described previously [35]; ns = no significant statistical significance determined between indicated transfected cells.

![Intracellular localization of LC/A4 and LC/A7](image)
3. Discussion

Earlier studies showed the LHD (residues 268–357) of BoNT/A1 was necessary for stable LC/A1 localization at the plasma membrane [35]. The current study’s structural analysis of LC/A1-SNAP-25 co-crystal (PDB: 1XTG) revealed that the LHD domain comprised three regions: R1, which was physically separated from SNAP-25; R2, which contributed to the SNAP-25 binding pocket; and R3, which was juxtaposed to a SNAP-25 α-helix. Utilizing EGFP-LC/A3V as a reporter platform [35], R1–R2, residues 275–334, termed the membrane localization domain (MLD), targeted EGFP-LC/A3V stably to the intracellular plasma membrane of N2A cells at 7 h and overnight steady-state expression (Figure 2). The 7 h post-transfection was investigated to observe if any EGFP-LC/A overexpression occurred at steady-state, leading to false-positive localization. As previously observed [35], adding the LC/A1 N terminus, residues 1–17, facilitated the transition to the plasma membrane (Figure 4). Loss of membrane localization for LC/A3V(A1R1) or LC/A3V(A1R2) supported roles for R1 and R2 to mediate a stable association with SNAP-25 (Figure 2). Interestingly, R1 may mimic another SNAP-25 binding protein, rabphilin-3a, targeting the N terminus of SNAP-25; we propose that this association, together with the association of R2 with the C terminus of SNAP-25, combine to mediate the stable co-localization with SNAP-25. These findings support the sequential step model for the intracellular localization of LC/A1 described in [35], where the N terminus of LC/A1 targets LC anterograde trafficking on vesicles, and the MLD targets LC/A1 to stably co-localize with SNAP-25 on the plasma membrane (Figure 9).

![Figure 9. Intracellular localization of BoNT/A subtypes- LC/A1, LC/A3LM, and LC/A3V. The N terminus (green N) associates LC/A1 and (yellow N) LC/A3LM with a synaptic vesicle, while the N terminus (red N) fails to associate LC/A3V with synaptic vesicles. LC/A1 MLD (green MLD) possesses a high affinity for localization at the plasma membrane where the (yellow MLD) LC/A3LM or (yellow MLD) LC/A3V fails to localize to the plasma membrane stably. LC/A3V can anterograde traffic (diffusion) to the plasma membrane but does not stably associate with the plasma membrane, while LC/A3LM can traffic to the plasma membrane but does not stably associate with the plasma membrane, leading to the three phenotypes of the respective LCs imaged.](image-url)

SNAP-25, a member of the SNARE family, is essential for exocytosis within neuronal cells. SNARE proteins are classified into five subfamilies depending on the structure, with SNAP-25 classified as a Qbc-SNARE [46]. While most SNARE proteins possess a transmembrane domain, SNAP-25 is a soluble protein that requires palmitoylation for association with the plasma membrane [47]. Before palmitoylation, SNAP-25 interacts with syntaxin-1, which is hypothesized to mediate the initial membrane binding of SNAP-25 [48,49]. After priming and uncoupling, SNAP-25 recycles to the trans-Golgi network and recycling endosomes before trafficking back to the plasma membrane [50]. While recycling back...
to the plasma membrane, SNAP-25 and LC/A1 remain segregated and populated on different vesicles, while LC/A1 co-localized with plasma membrane-associated SNAP-25 (Supplemental Figure S3), suggesting that the trafficking of LC/A1 to the plasma membrane mediated by the N terminal-17 amino acids of LC/A1 is uncoupled from SNAP-25 cycling to the plasma membrane. Our data support the current models for the trafficking pathway of SNAP-25.

Clustal alignment showed 100% identity for the MLDs of A1, A5, A6, and A8. LC/A2 was previously shown to localize with the plasma membrane despite having several conserved differences in the MLD relative to LC/A1 (Figure 7). LC/A4 and LC/A7 presented as membrane-localized proteins (Figure 8), demonstrating that despite amino acid differences within the MLD, residues that contribute to membrane localization are conserved. In contrast, the LC/A3 WT variant LC/A3 Loch Maree (LC/A3LM), which localizes on SV and the cytosol, has the lowest homology, 56.6% within the MLD relative to LC/A1 [35]. Our earlier data correlate with BoNT/A potency and intracellular localization, where A3LM and A3V have consecutively lower potency than A1 and increased cytosolic presence (Figure 9) [35,51].

The average duration of a eukaryotic protein is 90 min to 48 h [52–54]. Proteins with longer half-lives are classified as long-lived proteins (LLPs); these LLPs have been identified within synaptosomes and protein complexes [55]. In non-dividing cells such as neurons, components of the nuclear pore complex and some histones are preserved for years, as neurons within brains are hypothesized not to turn over [56–58]. Analyzing LLPs correlates membrane localization to protein duration, as cytosolic forms of the LLPs have a higher turnover rate than the respective plasma membrane LLP derivative [55]. The differences in localization suggest that cytosolic proteins are more accessible to the degradation machinery, resulting in a higher turnover. In addition to localization, two more factors have been shown to contribute to protein turnover: the primary sequence and incorporation into protein complexes or cellular structures [55]. The molecular basis for stable interactions between LLPs and intracellular membranes remains to be determined. Data show that in primary rodent neurons, the duration of action, a function of the LC, of BoNT/A1, BoNT/A2, and BoNT/A4 is >9 months, while that of BoNT/A3LM is <5 months [40,59]. Additionally, analysis of BoNT/A in a mouse model of botulism [39] showed a rapid recovery upon local intoxication with BoNT/A3 compared to BoNT/A1 and BoNT/A2. Analyzing the intracellular localization of the BoNT/A LCs: A1, A2, and A4 are plasma membrane-localized and co-localized with SNAP-25 [33–35] (Figure 8), while LC/A3LM is cytosolic and vesicle based [35]. Another protein interaction of LC/A1 that participates in stabilization may be the previously observed interaction of the C terminus, a deubiquitinating enzyme VCIP-135, which removes ubiquitin [60]. Therefore, intracellular localization and protein–protein interactions of BoNT/A LCs may be associated with duration of action, as subtypes with long durations, namely, A1, A2, A4, and A7, are membrane-localized. In contrast, shorter durations correlate with non-plasma membrane-localized LCs, such as LC/A3LM [39] and LC/E [61].

4. Conclusions

The current study provides novel insight into the mechanism behind the stable intracellular localization of LC/A1 in N2A cells, a model for primary motor neurons, based upon differences in the primary amino acid sequences of the LC/A subtypes, despite a conserved secondary amino acid structure. This level of refinement to identify unique host protein–BoNT interactions reveals new details that will aid in developing novel BoNT therapeutics and mechanisms targeting the duration of action of BoNTs.

5. Materials and Methods

5.1. Light Chain Structural Alignment

Co-crystal structures of BoNT LC/A1 bound to SNAP-25 (PDB: 1XTG) and LC/A3 Loch Maree (LM) (PDB: 7DVL) were obtained from the protein data bank (https://www.rcsb.org
5.2. BoNT-LC/A1 and /A3V Sequence Alignment

BoNT/A1 (ACS66881) and BoNT/A3 (ABY56337) were obtained from Uniprot [62] and aligned using the Blastp Suite (US National Library of Medicine) [63] to identify residues within regions of interest within the low homology domain (LHD) residues 268–357. Regions within the LC/A1 LHD were assigned: R1 (275–300), R2 (302–334), and R3 (335–357) (Supplemental Figure S4).

5.3. Engineering of GFP-LC/A3V (A1 LHD) Chimera Expression Plasmids

DNA encoding LC/A1 (1–450) and LC/A3V (1–446) were engineered as enhanced green fluorescent protein (EGFP)-fusions [35] within pEGFP-C3 by subcloning the LC genes into the SacI-BamHI restriction sites. New England Biolabs® NEBaseChanger® was used to design primers to engineer the chimeras EGFP-LC/A3V-A1, EGFP-LC/A3V(A1 275–300), EGFP-LC/A3V(A1 302–334), EGFP-LC/A3V(A1 335–357), EGFP-LC/A3V(A1 275–300, 335–357), EGFP-LC/A3V (A1 268–357), EGFP-LC/A3V (A1 1–17, 275–334), EGFP-LC/A3V (A1 287–334), and EGFP-LC/A3V (A1 275–334) T306 A, T307 A, Y312 A (Table 1).

5.4. Expression, Capture, and Analysis of Immunofluorescent EGFP-LC/A Plasmids

EGFP-LC/A expression plasmids were transfected into Neuro-2A (N2A) cells and scored following the protocol previously described [35]. Cells were plated onto 24-well plates (Fisher Scientific, Chicago, IL, USA) at a seeding density of 50,000 cells/well in complete essential media supplemented with 10% fetal bovine serum, 1 × penicillin–streptomycin, 0.1% sodium bicarbonate, 1 mM sodium pyruvate, and 1% nonessential amino acids in humidified 5% CO2 at 37 °C. The following day, N2A cells were transfected as described by the manufacturer (Lipofectamine LTX; Invitrogen™ (Waltham, MA, USA)) with 500 ng of the indicated plasmid in antibiotic-free complete essential media supplemented with 10% fetal bovine serum, 0.1% sodium bicarbonate, 1 mM sodium pyruvate, and 1% nonessential amino acids. Following a 7 h or overnight incubation, N2A cells were subjected to a membrane stain, wheat germ agglutinin (WGA): Alexa Fluor® 647 (1:1000), for 30 min at 4 °C. N2A cells were fixed with 4% paraformaldehyde for 15 min prior to staining with a nuclear marker, Hoechst (1:10,000), for five minutes and mounting to a glass coverslip with 8 µL of Prolong™ Gold Antifade Mountant (Invitrogen, Waltham, MA, USA). After staining, N2A cells were imaged on a Nikon Eclipse Ti-inverted microscope, using a 60× oil-immersion objective (1.4 NA objective) hardware with Eclipse software for data analysis. For each transfection condition, ten random fields of N2A cells were scored for EGFP localization for a total of ~100 N2A cells, as previously described [35]. EGFP empty vector co-localized in the cytosol and with Hoechst in the nucleus. Cells positive for membrane determined by localization with wheat germ agglutinin (WGA) were scored as a % of total cells utilizing the following equation [40]: (% of cells expressing membrane localization/total number of cells with EGFP fluorescence) × 100. Immunofluorescence results were graphed utilizing GraphPad Prism 9.3.1 (San Diego, CA, USA) and subjected to a statistical test using ordinary one-way ANOVA with Dunnett’s multiple comparisons with LC/A3V (A1-LHD) as the control column. Western blotting showed that each EGFP-LC/A fusion protein expressed and migrated to the correct molecular weight as indicated by SDS-PAGE (Supplemental Figure S2).

5.5. Live-Cell Imaging

Cells were plated and analyzed as previously described [35,64]. Cells were plated onto a 35 mm dish (MatTek, Ashland, MA, USA) at a seeding density of 300,000 cells in complete
essential media supplemented with 10% fetal bovine serum, 1× penicillin–streptomycin, 0.1% sodium bicarbonate, 1 mM sodium pyruvate, and 1% nonessential amino acids in humidified 5% CO₂ at 37 °C. The following day, N2A cells were transfected as described by the manufacturer (Lipofectamine LTX; Invitrogen™ (Waltham, MA, USA)) with 2000 ng of the indicated plasmid in antibiotic-free complete essential media supplemented with 10% fetal bovine serum, 0.1% sodium bicarbonate, 1 mM sodium pyruvate, and 1% nonessential amino acids. Seven hours post-transfection, N2A cells were live-imaged on a Nikon Eclipse Ti-inverted microscope using a 60× oil-immersion objective (1.4 NA objective) with a heated stage at 37 °C (Frank E. Fryer A-50) with Eclipse software for data analysis. Images were acquired every ten seconds for 10 min. Videos and images were compiled utilizing Nikon Elements AR 1.60.00 64-bit software (Melville, NY, USA) and Image J [65,66].

5.6. Western Blotting Confirming Chimera Molecular Weight

After overnight transfection, N2A cells were lysed using a 2× Protein Sample Buffer (150 µL) and boiled at 100 °C for five minutes. Cell lysates were resolved to a 13.5% SDS-PAGE and transferred to an Immobilon-P polyvinylidene difluoride membrane (PVDF) (Millipore, Billerica, MA, USA). PVDF membranes were fixed with methanol, air dried, rehydrated with methanol and rinsed in H₂O, and then incubated for 30 min in a blocking solution (2% powder milk w/v in 0.1% TBST). After blocking, PVDF membranes were probed with primary rat α-EGFP-monoclonal IgG (1:2000) (3H9, Chromotek, Planegg, Germany) for 60 min. Bound primary antibodies were recognized with α-rat IgG conjugated with horseradish peroxidase (1:10,000) (Life Technologies, Waltham, MA, USA). Secondary antibodies were visualized using Super Signal™ West Pico PLUS Chemiluminescent Substrate (34578, Thermo, Rockford, IL, USA) on an Azure C600 Imaging System (Dublin, CA, USA), using 20-second exposure.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/toxins14120814/s1, Figure S1: Intracellular localization of BoNT/A LC/A1; Figure S2: Western blotting of GFP-LC/A3V (A1-LHD) chimeras; Figure S3: Z-stack series of GFP-LC/A1 and SNAP-25; Figure S4: Blastp alignment of LC/A3 LM with LC/A1.

Author Contributions: Conceptualization, J.T.B. and S.P.; methodology, A.P.G., J.T.B. and S.P.; validation, A.P.G.; formal analysis, A.P.G., J.T.B. and S.P.; investigation, A.P.G.; resources, J.T.B. and S.P.; data curation, A.P.G.; writing—original draft preparation, A.P.G.; writing—review and editing, J.T.B. and S.P.; visualization, A.P.G., J.T.B. and S.P.; supervision, J.T.B. and S.P.; project administration, J.T.B. and S.P.; funding acquisition, J.T.B. and S.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by NIH AI139306.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The methods and data and supplementary data presented in this study are available.

Acknowledgments: We acknowledge the technical support of Amanda Przedpelski.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Thanongsaksrikul, J.; Chaicumpa, W. Botulinum neurotoxins and botulism: A novel therapeutic approach. Toxins 2011, 3, 469–488. [CrossRef]
2. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717–766. [CrossRef]
3. Sudhof, T.C.; Rothman, J.E. Membrane fusion: Grappling with SNARE and SM proteins. Science 2009, 323, 474–477. [CrossRef]
4. Ng, V.; Lin, W.J. Comparison of assembled Clostridium botulinum A1 genomes revealed their evolutionary relationship. Genomics 2014, 103, 94–106. [CrossRef] [PubMed]
5. Hill, K.K.; Xie, G.; Foley, B.T.; Smith, T.J.; Munk, A.C.; Bruce, D.; Smith, L.A.; Brettin, T.S.; Detter, J.C. Recombination and insertion events involving the botulinum neurotoxin complex genes in Clostridium botulinum types A, B, E and F and Clostridium butyricum type E strains. BMC Microbiol. 2009, 7, 66. [CrossRef] [PubMed]
6. Skarin, H.; Segerman, B. Horizontal gene transfer of toxin genes in Clostridium botulinum: Involvement of mobile elements and plasmids. Mob. Genet. Elem. 2011, 1, 213–215. [CrossRef] [PubMed]
7. Zhang, S.; Lebretón, F.; Mansfield, M.; Miyashita, S.-I.; Zhang, J.; Schwartzman, J.; Tao, L.; Masuyer, G.; Martínez-Carranza, M.; Stenmark, F.; et al. Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium. Cell Host Microbe 2018, 23, 169–176.e6. [CrossRef]
8. Zornetta, I.; Tehran, D.A.; Arrigoni, G.; Anniballi, F.; Bano, L.; Leka, O.; Zanotti, G.; Binz, T.; Montecucco, C. The first non-Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain. Sci. Rep. 2016, 6, 20257. [CrossRef]
9. Brunt, J.; Carter, A.T.; Stringer, S.C.; Peck, M.W. Identification of a novel botulinum neurotoxin gene cluster in Enterococcus. FEBS Lett. 2018, 592, 310–317. [CrossRef]
10. Hill, K.K.; Smith, T.J. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. In Current Topics in Microbiology and Immunology; Springer: Berlin/Heidelberg, Germany, 2013; Volume 364, pp. 1–20.
11. Wei, X.; Wentz, T.; Lobb, B.; Mansfield, M.J.; Zhen, W.; Tan, H.; Wu, Z.; Pellett, S.; Dong, M.; Doxey, A.C. Identification of divergent botulinum neurotoxin homologs in Paeniclostridium ghonii. bioRxiv 2022. [CrossRef]
12. Aoki, K.R.; Guyer, B. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. Eur. J. Neurol. 2001, 8 (Suppl. 55), 21–29. [CrossRef] [PubMed]
13. Singh, B.R. Scientific and Therapeutic Aspects of Botulinum Toxic; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2002; Volume 14.
14. Singh, B.R.; DasGupta, B.R. Conformational changes associated with the nicking and activation of botulinum neurotoxin type E. Biophys. Chem. 1990, 38, 123–130. [CrossRef] [PubMed]
15. Schiavo, G.; Rossetto, O.; Santucci, A.; DasGupta, B.R.; Montecucco, C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267, 23479–23483. [CrossRef] [PubMed]
16. Whelan, S.M.; Elmore, M.J.; Bodsworth, N.J.; Atkinson, T.; Minton, N.P. The complete amino acid sequence of the Clostridium botulinum type-E neurotoxin, derived by nucleotide-sequence analysis of the encoding gene. Eur. J. Biochem. 1992, 204, 657–667. [CrossRef]
17. Gardner, A.P.; Barbieri, J.T. Light Chain Diversity among the Botulinum Neurotoxins. Toxins 2018, 10, 268. [CrossRef]
18. Odumosu, O.; Nicholas, D.; Yano, H.; Langridge, W. AB toxins: A paradigm switch from deadly to desirable. Toxins 2010, 2, 1612–1645. [CrossRef]
19. Binz, T.; Sikorra, S.; Maharhold, S. Clostridial neurotoxins: Mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering. Toxins 2010, 2, 665–682. [CrossRef]
20. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898–902. [CrossRef]
21. Chen, S.; Kim, J.J.; Barbieri, J.T. Mechanism of substrate recognition by botulinum neurotoxin serotype A. J. Biol. Chem. 2007, 282, 9621–9627. [CrossRef]
22. Rummel, A. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. In Current Topics in Microbiology and Immunology; Springer: Berlin/Heidelberg, Germany, 2013; Volume 364, pp. 61–90.
23. Dong, M.; Yeh, F.; Tepp, W.H.; Dean, C.; Johnson, E.A.; Janz, R.; Chapman, E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312, 592–596. [CrossRef]
24. Colasante, C.; Rossetto, O.; Morbiato, L.; Pirazzini, M.; Molgó, J.; Montecucco, C. Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol. Neurobiol. 2013, 48, 120–127. [CrossRef] [PubMed]
25. Takeda, K.; Ueda, T. Effective Mechanism for Synthesis of Neurotransmitter Glutamate and its Loading into Synaptic Vesicles. Neurochem. Res. 2017, 42, 64–76. [CrossRef] [PubMed]
26. Hoch, D.H.; Romero-Mira, M.; Ehrlich, B.E.; Finkelstein, A.; DasGupta, B.R.; Simpson, L.L. Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: Relevance to translocation of proteins across membranes. Proc. Natl. Acad. Sci. USA 1985, 82, 1692–1696. [CrossRef] [PubMed]
27. Smart, O.; Breed, J.; Smith, G.; Sansom, M. A novel method for structure-based prediction of ion channel conductance properties. Biophys. J. 1997, 72, 1109–1126. [CrossRef]
28. Montecucco, C.; Schiavo, G.; Papini, E.; Rossetto, O.; De Bernard, M.; Tonello, F.; Moll, G.N.; Washbourne, P.E. Translocation of bacterial protein toxins across membranes. In Biochemistry of Cell Membranes. Molecular and Cell Biology Updates; Birkhäuser: Basel, Switzerland, 1995.
29. Falnes, P.O.; Olsnes, S. Cell-mediated reduction and incomplete membrane translocation of diphtheria toxin mutants with internal disulfides in the A fragment. J. Biol. Chem. 1995, 270, 20787–20793. [CrossRef]
30. Pirazzini, M.; Bordini, F.; Rossetto, O.; Shone, C.C.; Binz, T.; Montecucco, C. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett. 2013, 587, 150–155. [CrossRef]
31. Pirazzini, M.; Rossetto, O.; Eleopra, R.; Montecucco, C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol. Rev. 2017, 69, 200–235. [CrossRef]
32. Schiavo, G.; Rossetto, O.; Catsicas, S.; De Lauro, P.P.; Dasgupta, B.R.; Benfenati, F.; Montecucco, C. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J. Biol. Chem. 1993, 268, 23784–23787. [CrossRef]

33. Fernández-Salas, E.; Steward, I.E.; Ho, H.; Garay, P.E.; Sun, S.W.; Gilmore, M.A.; Ordás, J.V.; Wang, J.; Francis, J.; Aoki, K.R. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Natl. Acad. Sci. USA 2004, 101, 3208–3213. [CrossRef]

34. Chen, S.; Barbieri, J.T. Association of botulinum neurotoxin type A light chain with plasma membrane-bound SNAP-25. J. Biol. Chem. 2011, 286, 15067–15072. [CrossRef]

35. Gardner, A.; Tepp, W.H.; Bradshaw, M.; Barbieri, J.T.; Pellett, S. Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane. Int. J. Mol. Sci. 2021, 22, 11115. [CrossRef] [PubMed]

36. Smith, T.J.; Lou, J.; Geren, I.N.; Forsyth, C.M.; Tsai, R.; LaPorte, S.L.; Tepp, W.H.; Bradshaw, M.; Johnson, E.A.; Smith, L.A.; et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 2005, 73, 5430–5437. [CrossRef] [PubMed]

37. Kull, S.; Schulz, K.M.; Strotheimer, J.W.N.; Kirchner, S.; Schreiber, T.; Bollenbach, A.; Dabrowski, P.W.; Nitsche, A.; Kalb, S.R.; Donner, M.B.; et al. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype. PLoS ONE 2015, 10, e0116381. [CrossRef] [PubMed]

38. Rummel, A. The long journey of botulinum neurotoxins into the synapse. Toxicon 2015, 107 Pt A, 9–24. [CrossRef]

39. Pellett, S.; Tepp, W.H.; Whitemarsh, R.C.M.; Bradshaw, M.; Johnson, E.A. In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1–5. Toxicon 2015, 107 Pt A, 37–42. [CrossRef]

40. Pellett, S.; Bradshaw, M.; Tepp, W.H.; Pier, C.L.; Whitemarsh, R.C.M.; Chen, S.; Barbieri, J.T.; Johnson, E.A. The Light Chain Defines the Duration of Action of Botulinum Toxin A Subtypes. mBio 2018, 9, e00089-18. [CrossRef]

41. Winner, B.M.; Bodt, S.M.L.; McNutt, P.M. Special Delivery: Potential Mechanisms of Botulinum Neurotoxin Uptake and Trafficking within Motor Nerve Terminals. Int. J. Mol. Sci. 2020, 21, 8715. [CrossRef]

42. Breidenbach, M.A.; Brunger, A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432, 925–929. [CrossRef]

43. Leka, O.; Wu, Y.; Li, X.; Kammerer, R.A. Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3. J. Biol. Chem. 2021, 296, 100684. [CrossRef]

44. Madeira, F.; Pearce, M.; Tivey, A.R.N.; Basutkar, P.; Lee, J.; Edbali, O.; Madhusoodanan, N.; Lopez, R. Search and sequence analysis tools services from EMBL-EBI in 2022. Nucleic Acids Res. 2022, 50, W276–W279. [CrossRef]

45. Brown, N.P.; Leroy, C.; Sander, C. MView: A web-compatible database search or multiple alignment viewer. Bioinformatics 1998, 14, 380–381. [CrossRef] [PubMed]

46. Koike, S.; Jahn, R. SNARE proteins: Zip codes in vesicle targeting? J. Biol. Chem. 2001, 276, 325–329. [CrossRef] [PubMed]

47. Greaves, J.; Prescott, G.R.; Gorlekou, O.A.; Chamberlain, L.H. Regulation of SNAP-25 trafficking and function by palmitoylation. Biochem. Soc. Trans. 2010, 38 Pt 1, 163–166. [CrossRef] [PubMed]

48. Washbourne, P.; Cansino, V.; Mathews, J.R.; Burgoyne, R.D.; Wilson, M.C. Cysteine residues of SNAP-25 are required for SNARE disassembly and exocytosis, but not for membrane targeting. Biochem. J. 2001, 357 Pt 3, 625–634. [CrossRef] [PubMed]

49. Vogel, K.; Cabaniols, J.P.; Roche, P.A. Targeting of SNAP-25 to membranes is mediated by its association with the target SNARE syntaxin. J. Biol. Chem. 2000, 275, 2959–2965. [CrossRef]

50. Aikawa, Y.; Xia, X.; Martin, T.F. SNAP25, but not syntaxin 1A, recycles via an ARF6-regulated pathway in neuroendocrine cells. Mol. Biol. Cell 2006, 17, 711–722. [CrossRef]

51. Whitehouse, P.S.; Drigo, R.A.e.; Lev-Ram, V.; Ramachandra, R.; Deering, T.J.; Lehene, C.; Ellisman, M.H.; Hetzer, M.W. Visualization of long-lived proteins reveals age mosaicism within nuclei of postmitotic cells. J. Cell Biol. 2019, 218, 433–444. [CrossRef] [PubMed]

52. Whitehouse, P.S.; Drigo, R.A.e.; Lev-Ram, V.; Ramachandra, R.; Deering, T.J.; Lehene, C.; Ellisman, M.H.; Hetzer, M.W. Visualization of long-lived proteins reveals age mosaicism within nuclei of postmitotic cells. J. Cell Biol. 2019, 218, 433–444. [CrossRef] [PubMed]

53. Toyama, B.H.; Savas, J.N.; Park, S.K.; Harris, M.S.; Ingolia, N.T.; Yates, J.R., III; Hetzer, M.W. Identification of long-lived proteins reveals exceptional stability of essential cellular structures. Cell 2013, 154, 971–982. [CrossRef] [PubMed]

54. Toyama, B.H.; Drigo, R.A.e.; Lev-Ram, V.; Ramachandra, R.; Deering, T.J.; Lehene, C.; Ellisman, M.H.; Hetzer, M.W. Visualization of long-lived proteins reveals age mosaicism within nuclei of postmitotic cells. J. Cell Biol. 2019, 218, 433–444. [CrossRef] [PubMed]

55. Pellett, S.; Bradshaw, M.; Johnson, E.A.; Pellett, S. Persistence of botulinum neurotoxin A subtypes 1–5 in primary rat spinal cord cells. PLoS ONE 2014, 9, e90252. [CrossRef] [PubMed]
60. Tsai, Y.C.; Kotiya, A.; Kiris, E.; Yang, M.; Bavari, S.; Tessarollo, L.; Oyler, G.A.; Weissman, A.M. Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E5158–E5166. [CrossRef]

61. Fernández-Salas, E.; Ho, H.; Garay, P.; Steward, L.E.; Aoki, K.R. Is the light chain subcellular localization an important factor in botulinum toxin duration of action? *Mov. Disord. Off. J. Mov. Disord. Soc.* **2004**, *19* (Suppl. S8), S23–S34. [CrossRef]

62. Consortium, T.U. The universal protein knowledgebase in 2021. *Nucleic Acids Res.* **2021**, *49*, D480–D489. [CrossRef]

63. Shiryev, S.A.; Papadopoulos, J.S.; Schäffer, A.A.; Agarwala, R. Improved BLAST searches using longer words for protein seeding. *Bioinformatics* **2007**, *23*, 2949–2951. [CrossRef]

64. Zuverink, M.; Chen, C.; Przedpelski, A.; Blum, F.C.; Barbieri, J.T. A Heterologous Reporter Defines the Role of the Tetanus Toxin Interchain Disulfide in Light-Chain Translocation. *Infect. Immun.* **2015**, *83*, 2714–2724. [CrossRef]

65. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **2012**, *9*, 671–675. [CrossRef] [PubMed]

66. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. *Nat. Methods* **2012**, *9*, 676–682. [CrossRef] [PubMed]